MAP2K7 and neuroblastoma: To determine whether RXDX-105 treatment was also able to inhibit RET phosphorylation as well as the RAS-MAPK pathway in mice with neuroblastoma xenograft tumors, we evaluated lysates of harvested tumors by Western blots for total and phosphorylated RET, MEK, and ERK.